ES2139678T5 - Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion. - Google Patents

Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion.

Info

Publication number
ES2139678T5
ES2139678T5 ES94101461T ES94101461T ES2139678T5 ES 2139678 T5 ES2139678 T5 ES 2139678T5 ES 94101461 T ES94101461 T ES 94101461T ES 94101461 T ES94101461 T ES 94101461T ES 2139678 T5 ES2139678 T5 ES 2139678T5
Authority
ES
Spain
Prior art keywords
inhalation
preparation
pharmaceutical composition
pulmonary administration
erythropoyetin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94101461T
Other languages
English (en)
Other versions
ES2139678T3 (es
Inventor
Colin G Pitt
Robert M Platz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21760356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139678(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2139678T3 publication Critical patent/ES2139678T3/es
Publication of ES2139678T5 publication Critical patent/ES2139678T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

SE DESCRIBE EL USO DE ERITROPOIETINA (EPO) DE LA PREPARACION DE UNA COMPOSICION FARMACEUTICA PARA LA ADMINISTRACION PULMONAR O SU INHALACION. LA ADMINISTRACION POR AEROSOL DE EPO DE ACUERDO CON ESTA INVENCION DA COMO RESULTADO UNA ELEVACION SIGNIFICANTE DE GLOBULO ROJO EN LA SANGRE, LA EPO PUEDE SER ADMINISTRADA DE ESTA MANERA PARA TRATAR MEDICAMENTE O PREVENIR LA ANEMIA, ASI COMO PARA TRATAR O PREVENIR OTRAS ENFERMEDADES ASOCIADAS A LA ERITROPOIESIS.
ES94101461T 1993-02-04 1994-02-02 Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion. Expired - Lifetime ES2139678T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/013,514 US5354934A (en) 1993-02-04 1993-02-04 Pulmonary administration of erythropoietin

Publications (2)

Publication Number Publication Date
ES2139678T3 ES2139678T3 (es) 2000-02-16
ES2139678T5 true ES2139678T5 (es) 2003-12-01

Family

ID=21760356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94101461T Expired - Lifetime ES2139678T5 (es) 1993-02-04 1994-02-02 Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion.

Country Status (14)

Country Link
US (1) US5354934A (es)
EP (1) EP0613683B2 (es)
JP (1) JP4338214B2 (es)
AT (1) ATE187061T1 (es)
AU (1) AU677378B2 (es)
CA (1) CA2155334C (es)
DE (1) DE69421835T3 (es)
DK (1) DK0613683T4 (es)
ES (1) ES2139678T5 (es)
GR (1) GR3032374T3 (es)
HK (1) HK1009239A1 (es)
IL (1) IL108528A (es)
WO (1) WO1994017784A1 (es)
ZA (1) ZA94737B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956B2 (en) 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA2216443A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
AU706195B2 (en) * 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP1961760A3 (en) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
CA2252814A1 (en) * 1996-04-29 1997-11-06 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
ATE239447T1 (de) † 1997-09-29 2003-05-15 Inhale Therapeutic Syst In verneblern verwendbare, stabilisierte zubereitungen
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999054486A1 (en) * 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
MXPA01011429A (es) * 1999-05-11 2003-09-10 Ortho Mcneil Pharm Inc Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001087329A1 (en) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
CA2430318C (en) * 2000-11-29 2009-10-27 Itoham Foods Inc. Powder formulation and method for producing the same
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
ES2284858T3 (es) * 2001-02-02 2007-11-16 Ortho-Mcneil Pharmaceutical, Inc. Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
AU2002310054B2 (en) * 2001-05-21 2007-02-01 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
WO2003055526A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
CA2484676A1 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
PT1542714E (pt) 2002-09-18 2014-06-23 Janssen Pharmaceuticals Inc Métodos para aumentar a produção de células estaminais plaquetárias e hematopoiéticas
EP1852441B1 (en) 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
US7923032B2 (en) * 2002-11-26 2011-04-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
US20040132645A1 (en) * 2003-01-03 2004-07-08 Knox Susan J. Methods for modulating effects of radiation in a subject
EP2397128A1 (en) 2003-02-14 2011-12-21 Children's Hospital & Research Center at Oakland Use of L-arginine optionally combined with magnesium for the treatment of sickle cell disease and/or pulmonary hypertension
WO2004091495A2 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
TW200810773A (en) * 2006-04-19 2008-03-01 Alba Therapeutics Corp Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
CA2852683A1 (en) * 2011-10-17 2013-04-25 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
EP3272769B1 (en) 2012-01-26 2020-06-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US10105410B2 (en) 2014-03-10 2018-10-23 Rambam Med-Tech Ltd. Heparanase inhibitory peptides and use thereof for treating clinical pathologies
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
EP3658191A1 (en) 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Methods of protecting vascular integrity induced by targeted radiation therapy
MX2021008928A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
CA3127378A1 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
AU2020211412A1 (en) 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
EP3946417A1 (en) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
EP4007597A2 (en) 2019-08-01 2022-06-08 ACM Biolabs Pte Ltd A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
AU2021260857A1 (en) 2020-04-24 2022-11-03 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
AU2021396659A1 (en) 2020-12-11 2023-05-04 Acm Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CA3204785A1 (en) 2021-02-02 2022-08-11 Madhavan Nallani Sole use of polymersome associated adjuvant for stimulating an immune response
AU2022253567A1 (en) 2021-04-08 2023-11-23 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
JPS59163313A (ja) † 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
EP0257956B2 (en) † 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
JP2656944B2 (ja) † 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5469750A (en) 1991-03-05 1995-11-28 Aradigm Corporation Method and apparatus for sensing flow in two directions and automatic calibration thereof
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
GB9116610D0 (en) † 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
CA2127877A1 (en) † 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
CA2115444C (en) † 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration

Also Published As

Publication number Publication date
EP0613683B1 (en) 1999-12-01
JP4338214B2 (ja) 2009-10-07
EP0613683A1 (en) 1994-09-07
DK0613683T4 (da) 2003-07-14
US5354934A (en) 1994-10-11
WO1994017784A1 (en) 1994-08-18
ES2139678T3 (es) 2000-02-16
IL108528A0 (en) 1994-05-30
CA2155334C (en) 2006-08-15
DK0613683T3 (da) 2000-04-03
ZA94737B (en) 1994-09-29
AU677378B2 (en) 1997-04-24
ATE187061T1 (de) 1999-12-15
HK1009239A1 (en) 1999-05-28
DE69421835D1 (de) 2000-01-05
CA2155334A1 (en) 1994-08-18
GR3032374T3 (en) 2000-04-27
IL108528A (en) 1999-05-09
DE69421835T2 (de) 2000-05-18
EP0613683B2 (en) 2003-06-04
AU6098794A (en) 1994-08-29
DE69421835T3 (de) 2003-12-24
JPH08507753A (ja) 1996-08-20

Similar Documents

Publication Publication Date Title
ES2139678T3 (es) Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
NO170126C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater i form av suspensjoner som inneholder sucralfat
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
NO875299D0 (no) Insulinpreparat for ikke-paranteral administrasjon.
DK0416950T3 (da) Medikamenter
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
PT996462E (pt) Preparados de combinacoes farmaceuticas contendo eritropoietina e hemoglobinas modificadas
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
ATE32882T1 (de) Phenylnonatetraensaeurederivate, ihre herstellung und pharmazeutische praeparate mit diesen derivaten.
JPS6416890A (en) Antioxidant
DE69003466T2 (de) Substituierte Thienopyrimidin-Derivate, deren Herstellung, pharmazeutische Zusammensetzungen und medizinische Verwendung.
IT1199320B (it) 8-azaxantine alchilaminoalchil o eterociclilalchil sostituite sul nucleo triazolico,loro sali fisiologicamente accettabili,loro composizioni farmaceutiche ad attivita'antibroncospastica e relativo procedimento di preparazione
EP0341661A3 (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
IT1213568B (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IL83411A0 (en) Benzohydroxamic acid derivatives,their preparation and their use as herbicides
FR2582646B1 (fr) Nouveaux derives d'acetylmethadol et de propoxyphene, leur preparation et leur application en tant que medicaments
UA11695A1 (uk) Композиція іhгредієhтів для гіркої hастойки "житомирська ювілейhа"
IT8520150A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
ATE72439T1 (de) 3-propenylcephemderivate, ihre herstellung, zwischenverbindungen, pharmazeutische praeparate und anwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 613683

Country of ref document: ES